Outcomes of adult patients with type 1 primary refractory acute myeloid leukemia: a single center experience

References

• Short NJ, Rytting ME, Cortes JE. Acute myeloid leukaemia. Lancet. 2018 Aug 18;392(10147):593–606. doi:10.1016/S0140-6736(18)31041-9.
   PubMed Web of Science ®Google Scholar
• Buchner T, Schlenk RF, Schaich M, et al. Acute Myeloid Leukemia (AML): different treatment strategies versus a common standard arm–combined prospective analysis by the German AML intergroup. J Clin Oncol. 2012 Oct 10;30(29):3604–3610. doi:10.1200/JCO.2012.42.2907.
   PubMed Web of Science ®Google Scholar
• Burnett AK, Russell NH, Hills RK, et al. A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients. Blood. 2015 Jun 18;125(25):3878–3885. doi:10.1182/blood-2015-01-623447.
   PubMed Web of Science ®Google Scholar
• Döhner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022 Sep 22;140(12):1345–1377. doi:10.1182/blood.2022016867.
   PubMed Web of Science ®Google Scholar
• Ferguson P, Hills RK, Grech A, et al. An operational definition of primary refractory acute myeloid leukemia allowing early identification of patients who may benefit from allogeneic stem cell transplantation. Haematologica. 2016 Nov;101(11):1351–1358. doi:10.3324/haematol.2016.148825.
   PubMed Web of Science ®Google Scholar
• Wattad M, Weber D, Döhner K, et al. Impact of salvage regimens on response and overall survival in acute myeloid leukemia with induction failure. Leukemia. 2017 Jun;31(6):1306–1313. doi:10.1038/leu.2017.23.
   PubMed Web of Science ®Google Scholar
• McMahon CM, Perl AE. Management of primary refractory acute myeloid leukemia in the era of targeted therapies. Leuk Lymphoma. 2019 Mar;60(3):583–597. doi:10.1080/10428194.2018.1504937.
   PubMed Web of Science ®Google Scholar
• Roboz GJ, Rosenblat T, Arellano M, et al. International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed/refractory acute myeloid leukemia. J Clin Oncol. 2014 Jun 20;32(18):1919–1926. doi:10.1200/JCO.2013.52.8562.
   PubMed Web of Science ®Google Scholar
• Yamada K, Furusawa S, Saito K, et al. Concurrent use of granulocyte colony-stimulating factor with low-dose cytosine arabinoside and aclarubicin for previously treated acute myelogenous leukemia: a pilot study. Leukemia. 1995 Jan;9(1):10–14.
   PubMed Web of Science ®Google Scholar
• Zhang WG, Wang FX, Chen YX, et al. Combination chemotherapy with low-dose cytarabine, homoharringtonine, and granulocyte colony-stimulating factor priming in patients with relapsed or refractory acute myeloid leukemia. Am J Hematol. 2008 Mar;83(3):185–188. doi:10.1002/ajh.20903.
   PubMed Web of Science ®Google Scholar
• Zhou X, Mei C, Zhang J, et al. Epigenetic priming with decitabine followed by low dose idarubicin and cytarabine in acute myeloid leukemia evolving from myelodysplastic syndromes and higher-risk myelodysplastic syndromes: a prospective multicenter single-arm trial. Hematol Oncol. 2020 Oct;38(4):531–540. doi:10.1002/hon.2755.
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Rausch CR, Benton C, et al. Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. Am J Hematol. 2018 Mar;93(3):401–407. doi:10.1002/ajh.25000.
   PubMed Web of Science ®Google Scholar
• Daver N, Perl AE, Maly J, et al. Venetoclax plus gilteritinib for FLT3-mutated relapsed/refractory acute myeloid leukemia. J Clin Oncol. 2022 Dec 10;40(35):4048–4059. doi:10.1200/JCO.22.00602.
   PubMed Web of Science ®Google Scholar
• Montesinos P, Recher C, Vives S, et al. Ivosidenib and azacitidine in IDH1-mutated acute myeloid leukemia. N Engl J Med. 2022 Apr 21;386(16):1519–1531. doi:10.1056/NEJMoa2117344.
   PubMed Web of Science ®Google Scholar
• Shen Y, Chen J, Liu Y, et al. Addition of cladribine to idarubicin and cytarabine during induction increases the overall efficacy rate in adult patients with acute myeloid leukemia: A matched-pair retrospective comparison. Chemotherapy. 2014;60(5-6):368–374. doi:10.1159/000440943.
   PubMed Web of Science ®Google Scholar
• Meng T, Qi J, Zhu Y, et al. Impact of disease status at allogeneic stem cell transplantation on adolescent and young adult patients with early T-cell precursor acute lymphoblastic leukemia. Hematol Oncol. 2021 Aug;39(3):358–363. doi:10.1002/hon.2841.
   PubMed Web of Science ®Google Scholar
• Estey E. Why are there so few randomized trials for patients with primary refractory acute myeloid leukemia? Best Pract Res Clin Haematol. 2016 Dec;29(4):324–328. doi:10.1016/j.beha.2016.10.003.
   PubMed Web of Science ®Google Scholar
• Gyurkocza B, Lazarus HM, Giralt S. Allogeneic hematopoietic cell transplantation in patients with AML not achieving remission: potentially curative therapy. Bone Marrow Transplant. 2017 Aug;52(8):1083–1090. doi:10.1038/bmt.2017.8.
   PubMed Web of Science ®Google Scholar
• Rowe JM, Neuberg D, Friedenberg W, et al. A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the eastern cooperative oncology group. Blood. 2004 Jan 15;103(2):479–485. doi:10.1182/blood-2003-05-1686.
   PubMed Web of Science ®Google Scholar
• Pabst T, Vellenga E, van Putten W, et al. Favorable effect of priming with granulocyte colony-stimulating factor in remission induction of acute myeloid leukemia restricted to dose escalation of cytarabine. Blood. 2012 Jun 7;119(23):5367–5373. doi:10.1182/blood-2011-11-389841.
   PubMed Web of Science ®Google Scholar
• Löwenberg B, van Putten W, Theobald M, et al. Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia. N Engl J Med. 2003 Aug 21;349(8):743–752. doi:10.1056/NEJMoa025406.
   PubMed Web of Science ®Google Scholar
• Schmid C, Schleuning M, Schwerdtfeger R, et al. Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation. Blood. 2006 Aug 1;108(3):1092–1099. doi:10.1182/blood-2005-10-4165.
   PubMed Web of Science ®Google Scholar
• Mohty M, Malard F, Blaise D, et al. Sequential regimen of clofarabine, cytosine arabinoside and reduced intensity transplantation for primary refractory acute myeloid leukemia. Haematologica. 2017 Jan;102(1):184–191. doi:10.3324/haematol.2016.150326.
   PubMed Web of Science ®Google Scholar
• Ram R, Scheid C, Amit O, et al. Sequential therapy for patients with primary refractory acute myeloid leukemia: a historical prospective analysis of the German and Israeli experience. Haematologica. 2019 Sep;104(9):1798–1803. doi:10.3324/haematol.2018.203869.
   PubMed Web of Science ®Google Scholar
• Stelljes M, Middeke JM, Bug G, et al. In patients with relapsed/refractory AML sequential conditioning and immediate allogeneic stem cell transplantation (allo-HCT) results in similar overall and leukemia-free survival compared to intensive remission induction chemotherapy followed By allo-HCT: results from the randomized phase III ASAP trial. Blood. 2022;140(Supplement 1):9–11.
   Google Scholar
• Rashidi A, Hamadani M, Zhang MJ, et al. Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission. Blood Adv. 2019 Jun 25;3(12):1826–1836. doi:10.1182/bloodadvances.2019000050.
   PubMed Web of Science ®Google Scholar
• Yu S, Huang F, Wang Y, et al. Haploidentical transplantation might have superior graft-versus-leukemia effect than HLA-matched sibling transplantation for high-risk acute myeloid leukemia in first complete remission: a prospective multicentre cohort study. Leukemia. 2020 May;34(5):1433–1443. doi:10.1038/s41375-019-0686-3.
   PubMed Web of Science ®Google Scholar
• Xuan L, Wang Y, Huang F, et al. Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial. Lancet Oncol. 2020 Sep;21(9):1201–1212. doi:10.1016/S1470-2045(20)30455-1.
   PubMed Web of Science ®Google Scholar
• Kent A, Pollyea D, Winters A, et al. Venetoclax is safe and tolerable as post-transplant maintenance therapy for AML patients at high risk for relapse. Blood. 2020;136(Supplement 1):11–12.
   PubMedGoogle Scholar
• Kreidieh F, Abou Dalle I, Moukalled N, et al. Relapse after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia: an overview of prevention and treatment. Int J Hematol. 2022 Sep;116(3):330–340. doi:10.1007/s12185-022-03416-7.
   PubMed Web of Science ®Google Scholar